Hillsdale Investment Management’s Harmony Biosciences HRMY Stock Holding History

Hillsdale Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.85M	Hold	137,400	–	–	0.1%	243
2025 Q4	$5.14M	Hold	137,400	–	–	0.14%	194
2025 Q3	$3.79M	Buy	137,400 +16,700	+14%	+$575K	0.11%	243
2025 Q2	$3.81M	Buy	120,700 +50,500	+72%	+$1.62M	0.14%	207
2025 Q1	$2.33M	Buy	70,200 +2,200	+3%	+$78.9K	0.12%	199
2024 Q4	$2.34M	Buy	68,000 +300	+0.4%	+$10.3K	0.12%	205
2024 Q3	$2.71M	Buy	67,700 +900	+1%	+$31.6K	0.21%	177
2024 Q2	$2.02M	Sell	66,800 -2,800	-4%	-$84.2K	0.16%	194
2024 Q1	$2.34M	Buy	69,600 +5,700	+9%	+$183K	0.18%	180
2023 Q4	$2.06M	Sell	63,900 -300	-0.5%	-$8.37K	0.17%	182
2023 Q3	$2.1M	Hold	64,200	–	–	0.19%	170
2023 Q2	$2.26M	Sell	64,200 -11,400	-15%	-$394K	0.21%	160
2023 Q1	$2.47M	Hold	75,600	–	–	0.21%	144
2022 Q4	$4.17M	Buy	+75,600	New	+$4.16M	0.35%	110

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Hillsdale Investment Management's HRMY Position: Q1 2026 in Review

Hillsdale Investment Management held its Harmony Biosciences (HRMY) position steady in Q1 2026 at 137,400 shares worth $3.85M. The position accounts for 0.1% of the portfolio, ranked #243.

Hillsdale Investment Management first reported a position in HRMY in Q4 2022 and has held it in 14 quarters since. The position peaked at $5.14M in Q4 2025. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Hillsdale Investment Management held 137,400 shares of Harmony Biosciences worth $3.85M as of Q1 2026.
Hillsdale Investment Management left its Harmony Biosciences share count unchanged in Q1 2026.
Harmony Biosciences made up 0.1% of Hillsdale Investment Management's portfolio in Q1 2026, its #243 holding.
Hillsdale Investment Management first reported a position in Harmony Biosciences in Q4 2022 and has held it in 14 quarters since.
Hillsdale Investment Management's Harmony Biosciences position peaked at $5.14M in Q4 2025.
310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.